CAMBRIDGE, Mass., April 21, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that it has initiated a randomized Phase 1b/2 clinical trial evaluating IPI-926, its novel, oral Hedgehog pathway inhibitor, in combination with gemcitabine in patients with pancreatic cancer. In addition, Infinity reported new preclinical data on IPI-926 during the 2010 American Association of Cancer Research (AACR) Annual Meeting demonstrating that IPI-926 delays tumor re-growth after regression of the tumors by chemotherapy and by targeted therapy, further supporting the potential for Hedgehog pathway inhibition by IPI-926 in a broad range of difficult to treat cancers.
